$オキュラー・セラピューティクス(OCUL.US)$Have zero clue to this price action? Truly i can not figure why! Oh well lets see where it lands then decide whether to buy or wait?
1
9
報告
Jaguar8 :
Because people don’t understand how important it is.
Trytosaveabitスレ主Jaguar8:
Right as usual! But why today the big drop? It’s almost like people misread the study! The data was great compared to the placebo/control group? Hehehe! I truly can’t figure it?
$オキュラー・セラピューティクス(OCUL.US)$These results are actually really good! ZERO patients in control/placebo group had any improvement! But the actual group! Well here look for yourself! Then keep in mind coming into today there’s almost 12 million shares sold short! With 14 DTC at this volume! Hehehe! but I digress! Hehehe! (((((((((((((. Ocular Therapeutix (NASDAQ:OCUL) announced Thursday that its Phase 1 HELIOS ...
$オキュラー・セラピューティクス(OCUL.US)$Ocular Therapeutix - 46.2% of Patients Showed a 1- or 2-Step Improvement in Diabetic Retinopathy Severity Scale (Drss) at 40 Weeks in Axpaxli Arm Ocular Therapeutix Inc - No Patients in Axpaxli Group Experienced Worsening in Drss Compared to 12.5% in Control Arm at 40 Weeks
$オキュラー・セラピューティクス(OCUL.US)$ BofA has OCUL BUY PT 15 see the update positively given by Dr. Dugel's who’s expertise in retinal disease drug development. solid pwrsoective meanwhile we now await the upcoming readout of the phase 1 HELIOS trial in NPDR as the next BIG catalyst for the company ***** buy the RED day Dips and win?!? join to win a free Swing Channel for (6) months only 9 slots left from the 100 offered this morning in another platform. $ビームル・イメージング(BMR.US)$Tomorrow...
Despite strong revenue, the high P/S ratio suggests potential overvaluation. Investors' bullishness may lead to disappointment if P/S aligns with growth outlook. The share price risks decline due to mediocre revenue forecasts.
Petrus Advisers views Criteo as an 'attractive investment opportunity' that could be strengthened by requested actions. Ocular Therapeutix's leadership changes are seen as a positive step towards becoming a leader in retina care. Starboard previously labeled Fortrea shares as 'undervalued' and an 'attractive investment opportunity'.
($OCUL) - The Impact on Ocular Therapeutix. This funding is expected to significantly propel the company's research and development endeavors, especially the clinical development of AXPAXLI™ for wet AMD treatment. Wet AMD is a chronic eye disorder that causes blurred vision or a blind spot in your visual field. It's generally caused by abnormal blood vessels that leak fluid or blood into the region of the macula.$オキュラー・セラピューティクス(OCUL.US)$ ...
$オキュラー・セラピューティクス(OCUL.US)$Press Release: Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement Dow Jones· 2 mins ago
2
報告
Trytosaveabitスレ主 :
Ocular Therapeutix Announces $325M Private Placement Of 32,413,560 Shares At $7.52/Share And 10,805,967 Pre-Funded Warrants At $7.519/Warrant
Jaguar8 : Because people don’t understand how important it is.
Trytosaveabitスレ主 Jaguar8: Right as usual! But why today the big drop? It’s almost like people misread the study! The data was great compared to the placebo/control group? Hehehe! I truly can’t figure it?
Jaguar8 Trytosaveabitスレ主: Maybe explain it to them brother. They probably don’t even know what placebo means
Trytosaveabitスレ主 Jaguar8: Hehehe! You ass, I spit my coffee on my screen! OMG hehehe
Jaguar8 Trytosaveabitスレ主: Hahahaha
もっとコメントを見る...